Search - tctmd.com

Displaying 181 - 200 of 250

Sort: Relevancy | Date

News Conference News ESC 2017

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Michael O'Riordan

August 28, 2017

News Daily News

Evolocumab Not Cost-Effective at Current List Price

Michael O'Riordan

August 23, 2017

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

News Daily News

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Michael O'Riordan

August 01, 2017

News Conference News SCCT 2017

Coronary Calcium Scores in 2017: Useful, Yes, but Hard Outcomes Data Still Lacking

Yael L. Maxwell

July 13, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2017

Shelley Wood

June 01, 2017

News Features

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Michael O'Riordan

May 23, 2017

News Daily News

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

Michael O'Riordan

May 12, 2017

News Conference News EAS 2017

FOURIER in Focus: Costs, Patient Selection, Combination Therapy, and Safety Debated as Lipid Experts Digest the Data

Yael L. Maxwell

April 26, 2017

News Daily News

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Michael O'Riordan

April 04, 2017

News Conference News ACC 2017

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Yael L. Maxwell

March 23, 2017

News Conference News ACC 2017

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

Michael O'Riordan

March 19, 2017

News Conference News ACC 2017

ORION-1: Novel LDL-Lowering Treatment Could Reduce Costs, Increase Adherence Over PCSK9s

Yael L. Maxwell

March 17, 2017

News Conference News ACC 2017

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

Yael L. Maxwell

March 17, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Conference News ACC 2017

More Certainty With Ceramides? New Blood Test May Help ID CAD Patients Early in Disease

Yael L. Maxwell

March 09, 2017

News Daily News

Alirocumab to Remain On Market While Companies Clash Over Patents

Michael O'Riordan

February 09, 2017

News Daily News

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

Michael O'Riordan

February 03, 2017

News Daily News

How Low Can Cholesterol Go? Safety Not in Limbo for Patients With Very Low LDL on Alirocumab, Study Shows

Yael L. Maxwell

January 31, 2017

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

Advertisement

Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab

Evolocumab Not Cost-Effective at Current List Price

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

‘Remnant’ Cholesterol Linked With CVD Risk, Even When LDL Levels Are Low

Coronary Calcium Scores in 2017: Useful, Yes, but Hard Outcomes Data Still Lacking

TCTMD’s Top 10 Most Popular Stories for May 2017

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

FOURIER in Focus: Costs, Patient Selection, Combination Therapy, and Safety Debated as Lipid Experts Digest the Data

ACC/AHA ‘Very High Risk’ Criteria Only Modestly Predict Recurrent Events

Many Patients Prescribed PCSK9 Inhibitors Never End Up Getting Them

Going to Low LDL Levels With Evolocumab Does Not Affect Memory, Brain Function: EBBINGHAUS

ORION-1: Novel LDL-Lowering Treatment Could Reduce Costs, Increase Adherence Over PCSK9s

SPIRE 1 and 2: Support for PCSK9 Inhibition but Not Bococizumab

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

More Certainty With Ceramides? New Blood Test May Help ID CAD Patients Early in Disease

Alirocumab to Remain On Market While Companies Clash Over Patents

Major CVD Outcomes Trial Testing PCSK9 Inhibitor Evolocumab Meets Primary Endpoint

How Low Can Cholesterol Go? Safety Not in Limbo for Patients With Very Low LDL on Alirocumab, Study Shows

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content